Hisamitsu Pharmaceutical ... (HTSUF)
Hisamitsu Pharmaceutical Statistics
Share Statistics
Hisamitsu Pharmaceutical has 72.96M shares outstanding. The number of shares has increased by -8.26% in one year.
| Shares Outstanding | 72.96M |
| Shares Change (YoY) | -8.26% |
| Shares Change (QoQ) | -0.56% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 33.34M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 21.29 and the forward PE ratio is null. Hisamitsu Pharmaceutical's PEG ratio is 0.94.
| PE Ratio | 21.29 |
| Forward PE | n/a |
| PS Ratio | 2.1 |
| Forward PS | n/a |
| PB Ratio | 1.12 |
| P/FCF Ratio | 57.72 |
| PEG Ratio | 0.94 |
Enterprise Valuation
Hisamitsu Pharmaceutical has an Enterprise Value (EV) of 187.03B.
| EV / Sales | 1.32 |
| EV / EBITDA | 7.67 |
| EV / EBIT | 10.28 |
| EV / FCF | 36.3 |
Financial Position
The company has a current ratio of 4.22, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.22 |
| Quick Ratio | 3.76 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.09 |
| Debt / FCF | 0.41 |
| Interest Coverage | 731.5 |
Financial Efficiency
Return on Equity is 5.27% and Return on Invested Capital is 3.48%.
| Return on Equity | 5.27% |
| Return on Assets | 4.25% |
| Return on Invested Capital | 3.48% |
| Revenue Per Employee | $51.36M |
| Profits Per Employee | $5.06M |
| Employee Count | 2,759 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.96 |
Taxes
| Income Tax | 4.75B |
| Effective Tax Rate | 24.78% |
Stock Price Statistics
The stock price has increased by 31.51% in the last 52 weeks. The beta is 0.4, so Hisamitsu Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.4 |
| 52-Week Price Change | 31.51% |
| 50-Day Moving Average | 26.56 |
| 200-Day Moving Average | 25.06 |
| Relative Strength Index (RSI) | 99.97 |
| Average Volume (20 Days) | 3 |
Income Statement
In the last 12 months, Hisamitsu Pharmaceutical had revenue of 141.71B and earned 13.97B in profits. Earnings per share was 181.61.
| Revenue | 141.71B |
| Gross Profit | 78.97B |
| Operating Income | 13.17B |
| Net Income | 13.97B |
| EBITDA | 24.38B |
| EBIT | 19.2B |
| Earnings Per Share (EPS) | 181.61 |
Balance Sheet
The company has 112.46B in cash and 2.1B in debt, giving a net cash position of 110.36B.
| Cash & Cash Equivalents | 112.46B |
| Total Debt | 2.1B |
| Net Cash | 110.36B |
| Retained Earnings | 242.58B |
| Total Assets | 350.48B |
| Working Capital | 148.44B |
Cash Flow
In the last 12 months, operating cash flow was 18.19B and capital expenditures -13.04B, giving a free cash flow of 5.15B.
| Operating Cash Flow | 18.19B |
| Capital Expenditures | -13.04B |
| Free Cash Flow | 5.15B |
| FCF Per Share | 66.98 |
Margins
Gross margin is 55.73%, with operating and profit margins of 9.29% and 9.86%.
| Gross Margin | 55.73% |
| Operating Margin | 9.29% |
| Pretax Margin | 13.54% |
| Profit Margin | 9.86% |
| EBITDA Margin | 17.2% |
| EBIT Margin | 9.29% |
| FCF Margin | 3.64% |
Dividends & Yields
HTSUF pays an annual dividend of $0.3, which amounts to a dividend yield of 0.06%.
| Dividend Per Share | $0.30 |
| Dividend Yield | 0.06% |
| Dividend Growth (YoY) | -99.3% |
| Payout Ratio | 14.54% |
| Earnings Yield | 4.7% |
| FCF Yield | 1.73% |
Analyst Forecast
Currently there are no analyst rating for HTSUF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 2.09 |
| Piotroski F-Score | 7 |